Ovamex (Ganirelix)

Ganirelix blocks GnRH receptors in the pituitary gland, which stops the release of LH and FSH. By suppressing these hormones, it prevents the natural LH surge that would cause premature ovulation, allowing clinicians to control the timing of egg retrieval.

The specific dose and treatment schedule of Ovamex are determined by the prescribing physician based on the individual’s ovarian response and the protocol of the assisted reproduction program. Patients should follow the exact instructions provided by their healthcare professional.

Ovamex is intended for use before ovulation and is not administered during an established pregnancy. Its safety in breastfeeding has not been established, so it should be avoided in lactating women unless the prescriber decides the benefits outweigh potential risks.

To request Ovamex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Ovamex (ganirelix) is comparable to other GnRH antagonists such as cetrorelix in its mechanism of quickly suppressing LH surge. Differences may lie in formulation, dosing flexibility, and manufacturer‑specific excipients, but clinical efficacy and safety profiles are generally similar when used according to protocol.

Ovamex should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. Do not freeze the product, and avoid shaking the vial. Once removed from refrigeration, use within the time frame specified in the product labeling.

Ovamex is supplied as a sterile injectable solution for subcutaneous injection. The prescriber determines the injection site, typically the abdominal wall or thigh, and provides instructions on aseptic technique and timing relative to other fertility medications.

The most serious risks include severe ovarian hyperstimulation syndrome, allergic reactions that can progress to anaphylaxis, and rare thromboembolic events. Patients should be monitored closely for abdominal pain, rapid weight gain, shortness of breath, or any signs of an allergic response.

Ovamex is contraindicated in individuals with known hypersensitivity to ganirelix or any formulation components, in patients with active ovarian cysts that could worsen with stimulation, and in women who are already pregnant. Clinicians should also exercise caution in patients with severe cardiovascular or thromboembolic disorders.